Clinical Trials for Melanoma

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory advanced solid tumors who have exhausted or are unlikely to benefit from standard therapy receive autologous CRX100, activated immune cells carrying a tumor-selective oncolytic vaccinia virus, alone or with pembrolizumab. Eligible patients need measurable disease and ECOG performance status 0–1.

ClinicalTrials.gov ID: NCT04282044

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors and ECOG 0–1 are eligible for genotype-defined cohorts with KRAS, NRAS, or HRAS mutations; a separate cohort includes RAS–wild-type pancreatic ductal adenocarcinoma. All patients receive oral daraxonrasib (RMC-6236), a multiselective RAS(ON) inhibitor that blocks signaling by active RAS.

ClinicalTrials.gov ID: NCT05379985

A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 As a Single Agent and in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients with Advanced or Metastatic Solid Tumors (Keynote B59)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive GI-101 or GI-101A alone or in combination with pembrolizumab; GI-101 may also be combined with lenvatinib or local radiotherapy. GI-101 is a CD80–IL-2-variant fusion protein designed to counter CTLA-4-mediated suppression and stimulate cytotoxic T and natural-killer cells; GI-101A is a manufacturing-optimized formulation.

ClinicalTrials.gov ID: NCT04977453

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 As a Single Agent and in Combination Therapy in Patients with Selected Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with selected advanced solid tumors receive STK-012 alone or with pembrolizumab, with some cohorts also receiving pemetrexed and carboplatin; most dose-escalation cohorts require prior standard therapy, while some expansion cohorts allow untreated metastatic disease, including PD-L1-negative NSCLC. STK-012 is an investigational IL-2 receptor α/β-biased partial agonist designed to preferentially stimulate antigen-experienced CD25-positive T cells.

ClinicalTrials.gov ID: NCT05098132

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls patients with unresectable locally advanced or metastatic solid tumors who have exhausted, cannot tolerate, or are ineligible for standard therapy, with expansion cohorts focused on melanoma, renal cell carcinoma, and selected NSCLC. Patients receive imneskibart (AU-007), an anti-IL-2 antibody that blocks IL-2 binding to CD25, alone or with aldesleukin; some cohorts also receive avelumab or nivolumab.

ClinicalTrials.gov ID: NCT05267626

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients aged 16 years or older with previously treated advanced or metastatic solid tumors, including primary brain tumors, harboring BRAF V600 or eligible non-V600 class II or III alterations. Participants receive claturafenib (PF-07799933), an investigational brain-penetrant BRAF inhibitor, alone or with the MEK inhibitor binimetinib or the EGFR-targeting antibody cetuximab.

ClinicalTrials.gov ID: NCT05355701

Phase II Randomized Controlled Trial of Biologically Guided Stereotactic Body Radiation Therapy in Oligoprogressive Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with oligoprogressive NSCLC, melanoma, or renal cell carcinoma (1-5 progressing sites while on or after checkpoint inhibitor therapy) are randomized to receive either standard SBRT or a PET-guided, biologically adaptive SBRT approach that uses PET/CT to guide dose escalation to metabolically active tumor regions. All participants must have lesions suitable for SBRT and ECOG performance status ≤2.

ClinicalTrials.gov ID: NCT05830058

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors that have progressed after their most recent therapy receive investigational BMS-986340 alone or with nivolumab or docetaxel. BMS-986340 is an anti-CCR8 antibody designed to deplete tumor regulatory T cells.

ClinicalTrials.gov ID: NCT04895709

A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable solid tumors and ECOG 0–1 receive PF-08046054, a PD-L1-targeted antibody–drug conjugate that delivers the microtubule inhibitor MMAE, alone or with the PD-1 inhibitor pembrolizumab. Combination cohorts are limited to PD-L1-positive NSCLC or head and neck squamous cell carcinoma.

ClinicalTrials.gov ID: NCT05208762

A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with previously treated advanced solid tumors, including primary brain tumors, for PF-07799544, an investigational brain-penetrant MEK inhibitor. Combination cohorts enroll patients with BRAF-altered advanced melanoma or nonmelanoma solid tumors to receive PF-07799544 with PF-07799933, an investigational brain-penetrant BRAF inhibitor; an initial component may use encorafenib instead.

ClinicalTrials.gov ID: NCT05538130